LONDON, May 8, 2018 /PRNewswire/ --
Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and
life science company supporting medical innovation, today notes
that, its largest Group Business holding, Autolus Therapeutics
Limited (to be reorganised as Autolus Therapeutics plc)
("Autolus"), has filed a registration statement on Form F-1
("Registration Statement") with the U.S. Securities and Exchange
Commission (the "SEC") relating to a proposed initial public
offering ("IPO") in the United
States of its American Depositary Shares ("ADSs"), each
representing one ordinary share. All ADSs to be sold in the
proposed IPO will be offered by Autolus. Autolus intends to apply
to list its ADSs on the Nasdaq Global Market under the ticker
symbol "AUTL." The number of ADSs to be sold and the pricing terms
for the proposed IPO have not yet been determined.
Arix led the Series B financing of Autolus in March 2016, with Joe
Anderson, Arix's CEO, joining Autolus's Board of Directors.
Autolus has since progressed from a pre-clinical to clinical stage
company, with clinical trials currently ongoing for five programmes
in six indications.
The Registration Statement relating to the ADSs has been filed
with the SEC but has not yet become effective. The ADSs may not be
sold nor may offers to buy be accepted prior to the time the
Registration Statement becomes effective.
The Registration Statement can be accessed through the SEC's
EDGAR database and contains further information relating to
Autolus.
This announcement does not constitute an offer to sell or the
solicitation of an offer to buy securities, and shall not
constitute an offer, solicitation or sale in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that
jurisdiction.
The securities referred to in this announcement are to be
offered only by means of a prospectus. When available, copies of
the preliminary prospectus can be obtained from either of the joint
book-running managers for the offering, Goldman Sachs & Co.
LLC, Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at +1 866
471 2526 or by email at prospectusgroup-ny@ny.email.gs.com; or
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York,
NY 10022, or by telephone at + 1 877 547 6340, or by email
at Prospectus_Department@Jefferies.com.
About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science
company supporting medical innovation. Headquartered in
London and with an office in
New York, Arix Bioscience sources,
finances and builds world class healthcare and life science
businesses addressing medical innovation at all stages of
development. Operations are supported by privileged access to
breakthrough academic science and strategic relationships with
leading research accelerators and global pharmaceutical
companies.
Arix Bioscience plc is listed on the Main Market of the London
Stock Exchange.
About Autolus
Autolus is a biopharmaceutical company developing
next-generation programmed T cell therapies for the treatment of
cancer.
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Investor Relations
Manager
+44(0)20-7290-1072
charlotte@arixbioscience.com
Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Ivar
Milligan
+44(0)20-3709-5700
arix@consilium-comms.com